Zhejiang Wecome Pharmaceutical Co., Ltd. (300878) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Zhejiang Wecome Pharmaceutical Co., Ltd.

Why is Zhejiang Wecome Pharmaceutical Co., Ltd. ?

Poor Management Efficiency with a low ROCE of 5.02%

The company has been able to generate a Return on Capital Employed (avg) of 5.02% signifying low profitability per unit of total capital (equity and debt)

The company is Net-Debt Free

Poor long term growth as Net Sales has grown by an annual rate of -16.99% and Operating profit at -211.89% over the last 5 years
The company is Net-Debt Free
The company has been able to generate a Return on Equity (avg) of 4.63% signifying low profitability per unit of shareholders funds

Poor long term growth as Net Sales has grown by an annual rate of -16.99% and Operating profit at -211.89% over the last 5 years

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 128.64%, its profits have fallen by -16.1%
At the current price, the company has a high dividend yield of 0

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Zhejiang Wecome Pharmaceutical Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Zhejiang Wecome Pharmaceutical Co., Ltd.

111.44%

1.88

72.55%

China Shanghai Composite

21.43%

1.55

13.83%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-16.99%

EBIT Growth (5y)

-211.89%

EBIT to Interest (avg)

32.63

Debt to EBITDA (avg)

0.47

Net Debt to Equity (avg)

0.02

Sales to Capital Employed (avg)

0.22

Tax Ratio

12.29%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

ROCE (avg)

5.02%

ROE (avg)

4.63%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.19

EV to EBIT

-6.20

EV to EBITDA

-7.52

EV to Capital Employed

1.18

EV to Sales

5.03

PEG Ratio

Dividend Yield

ROCE (Latest)

-19.04%

ROE (Latest)

-22.55%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bullish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

20What is working for the Company

OPERATING CASH FLOW(Y)

Highest at CNY 52.68 MM

RAW MATERIAL COST(Y)

Fallen by -35.01% (YoY

NET SALES(Q)

At CNY 69.66 MM has Grown at 23.69%

PRE-TAX PROFIT(Q)

Highest at CNY 5.72 MM

NET PROFIT(Q)

Highest at CNY 1.74 MM

EPS(Q)

Highest at CNY 0.01

-13What is not working for the Company

CASH AND EQV(HY)

Lowest at CNY 339.34 MM

DEBT-EQUITY RATIO (HY)

Highest at 5.23 %

INTEREST(Q)

Highest at CNY 5.66 MM

Here's what is working for Zhejiang Wecome Pharmaceutical Co., Ltd.

Pre-Tax Profit

At CNY 5.72 MM has Grown at 111.67%

over average net sales of the previous four periods of CNY -49 MM

MOJO Watch

Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Operating Cash Flow

Highest at CNY 52.68 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (CNY MM)

Net Sales

At CNY 69.66 MM has Grown at 23.69%

over average net sales of the previous four periods of CNY 56.32 MM

MOJO Watch

Near term sales trend is positive

Net Sales (CNY MM)

Pre-Tax Profit

Highest at CNY 5.72 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 1.74 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

Net Profit

At CNY 1.74 MM has Grown at 103.25%

over average net sales of the previous four periods of CNY -53.72 MM

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.01

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost

Fallen by -35.01% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Zhejiang Wecome Pharmaceutical Co., Ltd.

Interest

At CNY 5.66 MM has Grown at 821.06%

period on period (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Interest

Highest at CNY 5.66 MM

in the last five periods and Increased by 821.06% (QoQ)

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Cash and Eqv

Lowest at CNY 339.34 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Debt-Equity Ratio

Highest at 5.23 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio